EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase III)Open Access · CC BY 4.0

Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials

Takaomi Kessoku, Toshikazu Akamatsu, Yasuhide Morioka iD, Takaaki Yokota, Masayuki Kobayashi, Kohei Uchida, Yuichi Koretaka, Atsushi Nakajima

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyae135 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Takaomi Kessoku und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Palliative Medicine and Gastroenterology, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan. Hauptthemen laut MEDLINE: Magnesium Oxide, Naltrexone, Neoplasms, Opioid-Induced Constipation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi & Co., Ltd, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the additive effect of naldemedine tosylate (naldemedine) on opioid-induced constipation in cancer patients insufficiently responding to magnesium oxide treatment.

Methods

We combined two randomized, double-blind, placebo-controlled, phase IIb and III trials of naldemedine and conducted a post hoc subgroup analysis. We evaluated the effect and safety of naldemedine in 116 patients who received naldemedine in addition to magnesium oxide (naldemedine group) and 117 patients who received placebo in addition to magnesium oxide (placebo group). Both groups included patients insufficiently responding to magnesium oxide for opioid-induced constipation. Effect was assessed using spontaneous bowel movement responder rate, complete spontaneous bowel movement responder rate, changes in spontaneous bowel movements and complete spontaneous bowel movements. Safety was also assessed.

Results

During the 2-week treatment period, the responder rates for spontaneous bowel movement and complete spontaneous bowel movement were 73.3 and 43.1% in naldemedine group, respectively, which were significantly higher (P < 0.0001) than 41.9 and 14.5% in placebo group, respectively. Median time to first spontaneous bowel movement and first complete spontaneous bowel movement was significantly shorter (P < 0.0001) in the naldemedine group (4.0 and 21.3 h, respectively) than in the placebo group (27.7 and 211.7 h, respectively). The incidence of adverse events and diarrhoea was significantly higher (P < 0.05) in the naldemedine group than in the placebo group, while the incidence of serious adverse events and severe diarrhoea was not significantly different between the naldemedine and placebo groups.

Conclusion

The study suggested the addition of naldemedine as an effective treatment option for opioid-induced constipation in cancer patients insufficiently responding to magnesium oxide treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnesium OxideNaltrexoneNeoplasmsOpioid-Induced ConstipationHumansMaleFemaleMiddle AgedDouble-Blind MethodAgedAdultAnalgesics, OpioidNarcotic AntagonistsConstipationDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

cancer managementclinical managementclinical trialsdrug discovery and deliveryquality of life

Substanzen

Magnesium OxidenaldemedineNaltrexoneAnalgesics, OpioidNarcotic Antagonists

Autor:innen und Institutionen

  • Department of Palliative Medicine and Gastroenterology, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan.
  • Department of Gastroenterology, International University of Health and Welfare Graduate School of Medicine, Narita, Chiba, Japan.
  • Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Medical Affairs Department, Shionogi & Co., Ltd, Chuo-ku, Osaka, Japan.
  • Clinical Research Department, Shionogi & Co., Ltd, Chuo-ku, Osaka, Japan.
  • Data Science Department, Shionogi & Co., Ltd, Chuo-ku, Osaka, Japan.

ORCID-Profile: Yasuhide Morioka

Förderung

  • Shionogi & Co., Ltd, Japan

Zitieren

APA

Kessoku, T., Akamatsu, T., Morioka, Y., Yokota, T., Kobayashi, M., Uchida, K., Koretaka, Y., & Nakajima, A. (2025). Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae135

Vancouver

Kessoku T, Akamatsu T, Morioka Y, Yokota T, Kobayashi M, Uchida K, et al. Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyae135

BibTeX
@article{Kessoku2025,
  author = {Kessoku, Takaomi and Akamatsu, Toshikazu and Morioka, Yasuhide and Yokota, Takaaki and Kobayashi, Masayuki and Uchida, Kohei and Koretaka, Yuichi and Nakajima, Atsushi},
  title = {Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyae135}
}
Kostenlos starten →